EU/3/18/2008

Table of contents

About

On 16 April 2018, orphan designation (EU/3/18/2008) was granted by the European Commission to Stolmàr & Partner Patentanwälte PartG mbB, Germany, for adeno-associated viral vector serotype 9 encoding miRNA against human superoxide dismutase 1 for the treatment of amyotrophic lateral sclerosis.

Key facts

Active substance
adeno-associated viral vector serotype 9 encoding miRNA against human superoxide dismutase 1
Disease / condition
Treatment of amyotrophic lateral sclerosis
Date of decision
16/04/2018
Outcome
Positive
Orphan decision number
EU/3/18/2008

Sponsor's contact details

Stolmár & Partner Patentanwälte PartG mbB
Blumenstrasse 17
80331 Munich
Germany
Tel. +49 89 23 23 670
E-mail: info@stolmar-ip.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating